Abemaciclib is a third generation CDK-directed drug used in the treatment of HR + /HER2 negative advanced or metastatic breast cancer. In a new study by Ines and co-workers, we demonstrate that members of the Homeodomain-interacting protein kinases (HIPKs) and DYRK1A are also targeted by abemaciclib. The therapeutic success of abemaciclib may therefore benefit from the simultaneous inhibition of the cell cycle regulating kinases Cdk4/Cdk6 in combination with off-target effects from the transcription kinases DYRK1A and HIPKs.
